Αποτελέσματα αναζήτησης - David D. Stenehjem
- Εμφανίζονται 1 - 8 Αποτελέσματα από 8
-
1
-
2
-
3
-
4
-
5
Real-world outcomes of immunotherapy–based regimens in first-line advanced non-small cell lung cancer από David Waterhouse, Jenny Lam, Keith A. Betts, Lei Yin, Sophie Gao, Yong Yuan, John Hartman, Sumati Rao, Solomon J. Lubinga, David D. Stenehjem
Έκδοση 2021Artigo -
6
Neutrophil-lymphocyte ratio as a predictive biomarker for response to high dose interleukin-2 in patients with renal cell carcinoma από James A. Kuzman, David D. Stenehjem, Joseph A. Merriman, Archana M. Agarwal, Shiven B. Patel, Andrew W. Hahn, Anitha Alex, Dan Albertson, David Gill, Neeraj Agarwal
Έκδοση 2017Artigo -
7
Circulating immune cell phenotype dynamics reflect the strength of tumor–immune cell interactions in patients during immunotherapy από Jason I. Griffiths, Pierre Wallet, Lance Pflieger, David D. Stenehjem, Xuan Liu, Patrick A. Cosgrove, Neena A. Leggett, Jasmine A. McQuerry, Gajendra Shrestha, Maura Rossetti, Gemalene Sunga, Philip J. Moos, Frederick R. Adler, Jeffrey T. Chang, Sunil Sharma, Andrea H. Bild
Έκδοση 2020Artigo -
8
American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer από Gary H. Lyman, Marc Carrier, Cihan Ay, Marcello Di Nisio, Lisa K. Hicks, Alok A. Khorana, Andrew D. Leavitt, Agnes Y.Y. Lee, Fergus Macbeth, Rebecca L. Morgan, Simon Noble, Elizabeth A. Sexton, David D. Stenehjem, Wojtek Wiercioch, Lara A Kahale, Pablo Alonso‐Coello
Έκδοση 2021Artigo
Εργαλεία αναζήτησης:
Σχετικά θέματα
Medicine
Internal medicine
Oncology
Cancer
Immunotherapy
Biology
Chemistry
Biochemistry
Clinical trial
Confidence interval
Gene
Lung cancer
Pembrolizumab
Absolute neutrophil count
Ambulatory
Atezolizumab
Avelumab
Bioinformatics
Biomarker
Bladder cancer
Bone marrow
Bortezomib
Cancer incidence
Cancer research
Carfilzomib
Cell
Center (category theory)
Chemotherapy
Cohort
Cohort study